Quick Links

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps highlight key elements of the Medical Crossfire®: RCC in an Era of Rapid Discovery: Key Questions online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Exelixis, Inc.

Medical Crossfire®: Renal Cell Carcinoma in an Era of Rapid Discovery: Key Questions

Release Date: January 30, 2017
Expiration Date: January 30, 2018
Media: Internet - based


Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of advanced renal cell carcinoma (RCC), including therapeutic sequencing, new targeted and immunotherapeutic agents, TKI resistance, and individualization of therapy. The Activity Chair, Robert Figlin, MD, along with our expert faculty, emphasize the cutting-edge clinical research that is already shaping their practice, or is likely to do so in the not-too-distant future.

During this 60-minute online CME-certified activity, the faculty exchange perspectives and opinions on 5 key clinically relevant questions related to therapeutic resistance, newly approved therapeutics, recently reported long-term overall survival data, subgroup analyses from landmark studies, treatment selection and sequencing, as well as real-world experiences with treatment-related side effects. Attendees will be given an opportunity to participate in a faculty-directed question and answer session.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Exelixis, Inc.

CME Activity Table of Contents

  • Welcome & Introductions
  • Resistance to Tyrosine Kinase Therapy for Renal Cell Carcinoma
  • Overall Survival and Subgroup Data for New Agents
  • Treatment Selection
  • Will Emerging Data From ESMO Change Your Practice?
  • Real-World Experience With Treatment-Related Side Effects
  • Evidence-Based Summary and Conclusion


Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, "educational content/video files" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and urologists who treat patients with renal cell carcinoma (RCC). Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare providers who are interested in the care of patients with RCC may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Explain targeted and immunotherapeutic mechanistic approaches to overcome anti-angiogenic resistance in the management of RCC
  2. Describe evidence-based approaches that inform optimized sequencing of current and emerging strategies for RCC
  3. Discuss proactive measures to manage and mitigate treatment-related side effects associated with approaches for advanced RCC
  4. Critically evaluate recent clinical trial data in the context of the established evidence guiding individualized treatment planning for patients with advanced RCC

Faculty, Staff, and Planners' Disclosures

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosure: No relevant financial relationships to disclose.

David F. McDermott, MD
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Boston, MA

Disclosure: No relevant financial relationships to disclose.

Robert J. Motzer, MD
Leader, Oncology Specialist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Bristol-Myers Squibb, Pfizer, Eisai, Exelixis, Novartis
Consultant: Pfizer, Novartis, Eisai, Exelixis.

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, PA

Disclosure: Grant/Research Support: Acceleron, AstraZeneca, Aveo, Bristol-Myers Squibb, Denderon, GSK, Eli Lilly Inc., Merck, Peloton, Pfizer Consultant: AstraZeneca, Bristol-Myers Squibb, Genentech, Eli Lilly Inc., Novartis, Pfizer, Roche, Synergene.

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive, Suite 100
Cranbury, NJ 08512
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705


Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By